Senior Management Team
Dr. Steiner founded and served as CEO to three publicly-traded drug-delivery companies: Biodel Inc. (Nasdaq: BIOD), MannKind Corp. (Nasdaq: MNKD), and Emisphere Technologies, Inc. (OTCQB: EMIS). Dr. Steiner served as Biodel’s Chairman, President and Chief Executive Officer from its inception in December 2003 through March of 2010. In 1991, Dr. Steiner founded Pharmaceutical Discovery Corporation ("PDC"), a biopharmaceutical corporation and is an inventor of its Technosphere™ Technology and MedTone™ Inhaler. Dr. Steiner served as PDC’s Chief Executive Officer and Chairman of the board of directors from its inception until December 2001, when PDC was merged with two other companies to form MannKind Corporation. From December 2001 to February 2003, Dr. Steiner served on MannKind’s board of directors and as a Corporate Vice President and Chief Scientific Officer. In 1985, Dr. Steiner founded and was Chairman of the board and President of Clinical Technologies Associates, Inc. ("CTAI"), now known as Emisphere Technologies, Inc. Under his leadership CTAI went public in February of 1989. Dr. Steiner is an inventor of Emisphere’s oral delivery technology for peptides and mucopolysaccharides.
Dr. Steiner is a Full Professor Emeritus at City University of New York, New York Medical College, a Research Full Professor of Psychiatry and Neurology at New York University School of Medicine and Adjunct Full Professor of Medical Science at Brown University.
Dr. Steiner serves as a member of the Board of Directors of the American Journal of Hypertension. Dr. Steiner was elected a Fellow of the American Psychological Association in 1973 for his work in psychopharmacology and has authored or co‑authored over 200 scientific publications. Dr. Steiner has served as a consultant to numerous pharmaceutical companies in connection with drug discovery and clinical efficacy testing. From 1966 till 1970 he was a Senior Research Scientist at Schering-Plough Corp. where he and his colleagues discovered and developed the first dopamine-2 receptor blockers. From 1964 to 1966 Dr. Steiner served as a Captain, Division of Neuropsychiatry, Walter Reed Army Institute of Research, U.S. Army. Dr. Steiner recieved a BA from New York University with a major in psychology and chemistry and a PhD from New York University.
Dr. Bakhru is an Adjunct Assistant Professor of Medical Science at Brown University where he was previously a Postdoctoral Fellow with Dr. Mathiowitz and winner of the 2008 Global MOOT Corp competition. Dr. Bakhru has co-authored over 20 publications, eight patents and one book chapter; his work has been published in 40 conference proceedings and abstracts. Dr. Bakhru received a BS in Biomedical Engineering from Columbia University, an MSE from Johns Hopkins University in Materials Science and a PhD from Carnegie Mellon University in Biomedical Engineering. In 2009, Dr. Bakhru received the Carnegie Mellon Tepper School of Business “Entrepreneur of the Year” alumni prize.
Dr. Laulicht was previously a Postdoctoral Fellow in the Harvard-MIT Health Sciences Technology program in the laboratories of Dr. Robert Langer and Dr. Jeffrey Karp. In 2012 he was named one of the 35 most innovative people under the age of 35 by MIT Technology Review.
Dr. Laulicht has co-authored eleven publications and 18 patents; his work has been published in nine conference proceedings and abstracts. Dr. Laulicht received a BA in Biophysics from Columbia University where he was an I.I. Rabi Science Research Scholar and a PhD in Medical Science from Brown University, conducting research in Dr. Mathiowitz's laboratory, for which he won the Joukowsky Outstanding Dissertation Award.
Mr. Steiner has more than twenty years of operational and senior management experience. He cofounded Biodel Inc. (Nasdaq: BIOD) in 2003 and served as a member of the executive management team and Vice President of Operations until 2014. From 1999 to 2003, Mr. Steiner served as Head of Operations of CMI, a film and television production company, producing projects for Virgin Atlantic, Touchstone Television, and Disney, among others.
From 1994 to 1996 Mr. Steiner served as Operations Manager for the Atlantic Coast Brewing Company start-up in Boston, and the Black Diamond Brewing Company start-up in the San Francisco Bay area. From 1996 to 1999 Mr. Steiner launched and oversaw manufacturing and packaging operations for two MGM Resorts International (NYSE: MGM) ventures, formerly Mirage Resorts and Circus Circus Enterprises (NYSE: CCE), in Las Vegas, Nevada ranking first in statewide production and third in the southwestern U.S.
From 1989 to 1994 Mr. Steiner served as Administrative Director and Fiscal Administrator of the New Jersey Public Interest Research Group overseeing the operations of five corporations with offices in twelve cities. He sat on a national board of thirty organizations, developing national policies and guidelines. Mr. Steiner conducted national training seminars in operations, financial management, fundraising and district organizing strategies for the National Environmental Law Center, the Fund for Public Interest Research and Green Corps (an AmeriCorps project).
Mr. van Straelen is the former President of U.S. Operations and Executive Vice President for Worldwide Sales and Marketing for Akzo Nobel N.V.’s business unit, Diosynth, the largest manufacturer of heparin for pharmaceutical use. He received an MSc in Biochemistry from the University of Amsterdam.
Mr. Sussman is Managing Partner of The Channel Group, LLC, served as a member of senior management (Head of Business Development, CFO, and CEO) of several public and private biotechnology companies, including Perlegen Sciences, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corp. In these positions he established collaborations with major pharmaceutical companies, including AstraZeneca AB, Bristol-Myers Squibb Co., Eli Lilly & Co., GlaxoSmithKline plc, Pfizer Inc., Solvay Pharmaceuticals B.V., and Unilever plc that provided in aggregate more than $100 million in research funding and equity investments. His deal sheet lists 27 significant life sciences transactions, including an IPO on NASDAQ. He also initiated and was responsible for in-licensing of late-stage clinical and pre-clinical drug candidates. Prior to those positions, he was Director of Strategy & Business Development at Ciba-Geigy Corp.'s (now Novartis) Pharmaceuticals Division.
Mr. Sussman is on the Board of Directors of Thar Pharmaceuticals, Inc. and was a founder and member of the Board of Lesanne Life Sciences, LLC. He was a member of the Board of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (LCT: ASX). In addition, he previously served as a member of the Board of Directors and management of Phage Pharmaceuticals, Inc., a specialty biopharmaceutical manufacturer and developer of therapeutic proteins. Mr. Sussman has a BS in Physics from Stony Brook University, a Master of Science in Biotechnology from Manhattan College, and an SM in Management with a concentration in Finance from the Sloan School of Management, MIT.